Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.53 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | PLG | P00747 | 4/20 | 0.49 |
| ▸ | KLK1 | P06870 | 4/20 | 0.49 |
| ▸ | KLK6 | Q92876 | 4/20 | 0.49 |
| ▸ | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | P62805 | 1/20 | 0.48 |
| ▸ | EP300 | Q09472 | 1/20 | 0.48 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.48 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.48 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26565236 | 0.86 | ALDH1A1 (0.48) | NPC1RAB9AALOX15H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16EP300 | |
| SCHEMBL26565011 | 0.86 | TRPV1 (0.59) | NPC1RAB9AALOX15GAAKDM4E | |
| SCHEMBL17774884 | 0.83 | NPC1 (0.63) | NPC1RAB9AH4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16EP300PRMT1 | |
| SCHEMBL26564714 | 0.83 | TRPV1 (0.48) | NPC1RAB9AALOX15PLGKLK1 | |
| SCHEMBL26564737 | 0.80 | NPC1 (0.50) | NPC1RAB9APLGKLK1KLK6 | |
| SCHEMBL26564771 | 0.79 | TRPV1 (0.49) | NPC1RAB9AHSD17B10CHRNB2CHRNB4 | |
| SCHEMBL330342 | 0.78 | KDR (0.65) | NPC1RAB9AH4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16EP300PRMT1 | |
| SCHEMBL31722789 | 0.77 | NPC1 (0.61) | NPC1RAB9APLGKLK1KLK6 | |
| SCHEMBL29575361 | 0.77 | NPC1 (0.61) | NPC1RAB9APLGKLK1KLK6 | |
| SCHEMBL2743115 | 0.77 | NPC1 (0.61) | NPC1RAB9APLGKLK1KLK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331663-A1 | SMALL MOLECULE NICOTINAMIDE ADENINE DINUCLEOTIDE MODULATORS | THE CLEVELAND CLINIC FOUNDATION | 2023-10-19 | — | — | US | disclosed |
| US-20230331663-A1 | SMALL MOLECULE NICOTINAMIDE ADENINE DINUCLEOTIDE MODULATORS | THE CLEVELAND CLINIC FOUNDATION | 2023-10-19 | — | — | US | disclosed |
| US-20230331663-A1 | SMALL MOLECULE NICOTINAMIDE ADENINE DINUCLEOTIDE MODULATORS | THE CLEVELAND CLINIC FOUNDATION | 2023-10-19 | — | — | US | disclosed |
| WO-2022082114-A1 | SMALL MOLECULE NICOTINAMIDE ADENINE DINUCLEOTIDE MODULATORS | THE CLEVELAND CLINIC FOUNDATION (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331663-A1 | SMALL MOLECULE NICOTINAMIDE ADENINE DINUCLEOTIDE MODULATORS | NQO1, NADK, CD38 | NPC1 556/4885RAB9A 1251/4885ALOX15 1700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.